TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Demonstrate the Efficacy of Cangrelor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~To be included in this study, subjects must meet the following criteria:~* Angiography demonstrating atherosclerosis amenable to treatment by percutaneous coronary intervention (PCI) with or without stent implantation and diagnosis of Acute Coronary Syndrome (ACS) by elevated cardiac markers or ischemic chest discomfort w/electrocardiogram changes + age \> 65 or diabetes or ST-elevation MI.~EXCLUSION CRITERIA~Subjects will be excluded from the study if they present with any of the following:~1. Not a candidate for PCI~2. Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (\<1 month) trauma or major surgery (including by-pass surgery); currently receiving warfarin, active bleeding~3. Impaired hemostasis: known International Normalized Ratio (INR) \>1.5 at screening; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count \<100,000/µL), or history of thrombocytopenia or neutropenia associated with clopidogrel~4. Severe hypertension not adequately controlled by antihypertensive therapy at the time of randomization~5. Receipt of fibrinolytic therapy in the 12 hours preceding randomization~6. Receipt of clopidogrel dose exceeding maintenance dose (ie, \>75 mg) at any time in the 5 days preceding randomization~7. Inability to swallow study capsules~8. Glycoprotein IIb/IIIa (GPI) Inhibitor usage within the previous 12 hours \[applicable to unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) patients\]~Subjects excluded for any of the above reasons may be re-screened for participation at any time if the exclusion characteristic has changed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cangrelor (Type: EXPERIMENTAL): placebo capsules (to match) + cangrelor bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + active clopidogrel (600mg) post infusion
- Clopidogrel (Type: ACTIVE_COMPARATOR): clopidogrel capsules (600 mg) + placebo bolus \& infusion (to match) + placebo capsules (to match) post infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of:~  * Acute myeloid or lymphoid leukemia in remission,~ * Myelodysplastic syndrome,~ * Chronic lymphoid leukemia,~ * Non-Hodgkin lymphoma,~ * Hodgkin lymphoma,~ * Chronic myeloid leukemia in chronic or accelerated phase,~ * Myeloproliferative disorder, or~ * Multiple myeloma~* Undergoing allogeneic HSC transplantation from a related or unrelated donor matched at least at 7 of 8 of the HLA-A, -B, -C, and DR loci (8/8 or 7/8 match)~* Undergoing allogeneic HSC transplantation after a myeloablative TBI-, busulfan-, or (non-myeloablative) melphalan-based pre-transplant conditioning regimen. Regimens for transplantation will include at one of the following agents, given in conjunction with fludarabine or cyclophosphamide:~  * Busulfan 130 mg/m2 iv daily x 2 (reduced intensity) or 4 days~ * TBI 150 cGy bid x8 doses (1200 Gy)~ * Melphalan 140 mg/m2. (Although melphalan is not a myeloablative regimen, it results in clinically significant mucositis and patients receiving this medication will be of considerable interest in the analysis of these data.)~* Male or female patient age 18 years or older~* Karnofsky performance status \> 70% at time of initiation of pre-transplant conditioning~* Transplantation-specific co-morbidity score of \<5 at time of initiation of pre-transplant conditioning~* Patients taking antihypertensive medications (including telmisartan) are eligible but the patient must discontinue treatment at least 48 hours prior to first dose of study medication~* Capable of giving informed consent and having signed the informed consent form~Exclusion Criteria:~* Inability to provide informed consent~* Subjects with known heart failure, advanced renal impairment requiring renal replacement therapy, or liver failure although these patients would most likely not be eligible for HCT.~* Subjects taking ACE inhibitors, potassium supplements, or spironolactone (or any other potassium-sparing diuretics) who cannot discontinue use prior to initiation of study treatment OR who require a high-potassium diet~* Patient unable to discontinue current hypertension medication for medical or other reasons for two days prior to starting telmisartan~* Chronic symptomatic hypotension, volume depletion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 160 mg Telmisartan (Type: EXPERIMENTAL): 60 patients will receive 160 of Telmisartan (2 80 mg tablets) for 101 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Smoking Cessation Interventions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* active tobacco use~* preoperative appointment for an operation within 6 weeks~Exclusion Criteria:~* active enrollment in tobacco cessation program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control: Prescriptive Advice (Type: NO_INTERVENTION): Amenable patients will be enrolled into the study, their intervention will be current standard of care smoking cessation counseling by their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
- Intervention1: Contract Agreement (Type: EXPERIMENTAL): Amenable patients will be enrolled into the study, their intervention will be a smoking cessation contract with their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
- Intervention2: Implementation Intentions (Type: EXPERIMENTAL): Amenable patients will be enrolled into the study, their intervention will be a worksheet to fill out with their smoking cessation implementation intentions that will be signed by patient and surgeon, they will undergo 3 urine tests and a chart review for outcomes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patients With Heart Failure ANd Type 2 Diabetes Treated With Placebo Or Metformin (PHANTOM) Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All subjects with physician-diagnosed symptomatic heart failure (NYHA class I, II, III, IV) and type 2 diabetes.~A diagnosis of type 2 diabetes defined as:~* a previous physician diagnosis of type 2 diabetes as documented in the subject's clinical record or;~* receiving oral antihyperglycemic agents or;~* a new diagnosis of type 2 diabetes during the visit within the heart failure clinic or hospital based on a fasting blood glucose ≥7.0 mmol/L or random blood glucose ≥11.1 mmol/L accompanied by acute metabolic decompensation or 2 hour plasma glucose in a 75 gram oral glucose tolerance test ≥11.1 mmol/L.~Exclusion Criteria:~* subjects currently receiving greater than 1500 mg of metformin therapy per day~* subjects who are unwilling to change their antidiabetic regimens;~* subjects receiving insulin therapy;~* serum creatinine ≥ 180 μmol/L;~* A1c \< 7.0 percent;~* inability to communicate (language barrier);~* dementia/mental illness;~* age \< 18 years;~* subjects unwilling to complete self-monitoring of serum blood sugars during the trial period.~* those participating in another heart failure or diabetes clinical trial involving medication;~* severe comorbidities or foreshortened life expectancy;~* subjects who do not provide written informed consent to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has had SARS-CoV-2 positive antigen, RT-PCR, or other locally approved molecular diagnostic assay obtained within 5 days prior to randomization~* Has had symptoms consistent with COVID-19 with onset 5 days before randomization~* Has one or more COVID-19-related signs or symptoms on the day of randomization~* Phase 2: Is an adult aged 18 years and above~* Phase 3: Is an adult aged 18 years and above or is an adolescent aged 12 to 17 years (inclusive) and weighing ≥40 kg at the time of screening~Exclusion Criteria:~* Is currently hospitalized or in the opinion of the investigator is anticipated to require hospitalization within 48 hours of randomization.~* Has severe COVID-19 or is on supplemental oxygen~* Has a history of a positive SARS-CoV-2 antibody serology test~* Has participated, within the last 30 days, in a clinical study involving an investigational intervention~* Has received a SARS-CoV-2 vaccine, monoclonal antibody, or plasma from a person who recovered from COVID-19 any time prior to participation in the study~NOTE: Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADG20 IM (Type: EXPERIMENTAL): Participants will be dosed on Day 1 with ADG20 IM
- Placebo IM (Type: PLACEBO_COMPARATOR): Participants will be dosed on Day 1 with placebo IM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnostic of chronic granulomatous disease (CGD) with determined genetic form~* for minors, patient requiring installation or removal of deep venous general anesthesia.~Exclusion Criteria:~* patients with acute infections scalable to practice of skin biopsy under local anesthesia~* patient with impaired hemostasis acquired (drug) or innate.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic Granulomatous Disease (Type: EXPERIMENTAL): Sample collection were performed from patients with chronic granulomatous disease linked to X or due to Autosomal Recessive (AR) forms AR220, AR470 and AR670.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Chitosan for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion:~1. Confirmation of adenocarcinoma of the prostate that is documented by one of the following: pathology report or clinic note with documented history of prostate cancer.~2. Subjects must be receiving ADT with a GnRH agonist or antagonist, with or without an anti-androgen or testosterone synthesis inhibitor. The current testosterone level must be documented to be \<50ng/dL at enrollment. Subjects whose ADT is interrupted may enroll or continue on study as long as the testosterone is documented to remain \<50ng/dL for the entire duration of study participation. Subjects who have undergone orchiectomy are also eligible.~3. Subjects must have adequate hematologic, renal, and hepatic function at baseline, as follows:~   * Hematology parameters: ANC \>1000/mcL, platelets \> 100,000/mcL, Hgb \>8.0gm/dL~  * Renal Function: eGFR of ≥ 45mls/min using Cockgroft and Gault formula~  * Liver Function: Total bilirubin ≤ULN, AST and ALT \<1.5x ULN~4. Able to swallow and retain oral medication~5. ECOG performance status of 0 - 2~6. Ability to sign written informed consent~7. Testosterone level \<50ng/dL at time of enrollment.~8. Age 18 or older.~9. May have had prior radiation therapy, surgery, or cryoablation for primary prostate cancer~10. May have had prior cytotoxic chemotherapy for metastatic prostate cancer, prior treatment with genomically-targeted agents, or Provenge~Exclusion:~1. Known allergy to chitosan or shellfish.~2. History of receiving more than 2 classes of ADT.~3. Chronic constipation (BM \< 3x weekly), history of malabsorption or history of daily laxative use.~4. Patients requiring medication administration with lunch or dinner or at a frequency of three or more times per day are not eligible.~5. Current use of chitosan, sevelamer, and/or glucosamine.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chitosan dose escalation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, aged 18 years or older with unresectable or metastatic melanoma.~* A life expectancy of \>12 weeks.~* Laboratory ranges and medical criteria met, as defined within the protocol.~* Subject may have received more than 1 prior regimen of systematic treatment for unresectable or metastatic melanoma.~* For Phase 2 period of the study only, Subjects must have archival tumor tissue available and collected with the prior 6 months or accessible disease for pre-treatment, study biopsy.~Exclusion Criteria:~* Pregnant or nursing women.~* Current investigational trial participation with another investigational product or subjects who have received any anticancer medications within 21 days prior to screening (6 weeks for mitomycin-C or nitrosoureas.)~* Subjects receiving monoamine oxidase inhibitors (MAOI)s; subjects who have ever had Serotonin Syndrome after receiving one or more serotonergic drugs.~* Subjects who have received prior immune checkpoint inhibitors (eg anti-CTLA-4, anti-PD-1, anti- PD-L1 and others) who have had Grade 3 or 4 hepatotoxicity, immune colitis requiring infliximab, endocrine toxicity not controlled by replacement, any other Grade 4 immune adverse events (AEs) or ocular toxicity~* Subjects with protocol-specified active autoimmune process except vitiligo or thyroiditis.~* Subjects with concurrent conditions that would jeopardize the safety of the safety of the subject or compliance with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epacadostat 300 mg (Type: EXPERIMENTAL): 300 mg twice daily (BID) in combination with ipilimumab
- Placebo in combination with ipilimumab (Type: PLACEBO_COMPARATOR): None
- Epacadostat 25 mg (Type: EXPERIMENTAL): 25 mg BID in combination with ipilimumab
- Epacadostat 50 mg (Type: EXPERIMENTAL): 50 mg BID in combination with ipilimumab
- Epacadostat 75 mg (Type: EXPERIMENTAL): 75 mg once a day (QD) in combination with ipilimumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Aspirin on Patency of Metal Stent in Malignant Distal Bile Duct Obstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Malignant distal bile duct obstruction~* Over 20 years old~* Techinical success of endoscopic retrograde biliary drainage with metalic stent~Exclusion Criteria:~* Patient's denial~* Previous Aspirin use~* Aspirin allergy~* Contraindication for aspirin~* Life expectancy \< 6mo~* Gastroduodenal ulcer~* History of substance abuse~* Participation in a clinical trial within the past 30 days

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Intervention : aspirin medication Case with aspirin medication for 6 months after stenting
- Control (Type: PLACEBO_COMPARATOR): Control : placebo medication Case with placebo medication for 6 months after stenting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Coherence Therapy for Procrastination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Being a student~* 19-26 years old~* A score above 51 on the General Procrastination Scale~Exclusion Criteria:~* Being currently under a psychological treatment~* Being diagnosed lately with any mental disorder~* Mental retardation~* Substantial visual, hearing or cognitive deficits~* Psychotic symptoms~* Organic brain dysfunction

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- Coherence Therapy (Type: EXPERIMENTAL): Individual treatment with Coherence Therapy: three one-hour sessions + one booster session.
- Cognitive Behavioral Therapy (Type: ACTIVE_COMPARATOR): Individual treatment with Cognitive Behavioral Therapy: three one-hour sessions + one booster session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Accelerated Titration of Oxytocin for Nulliparous Patients With Labour Dystocia: ACTION Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Capability of participant to comprehend English and/or French and to comply with study requirements~2. ≥ 18 years of age at time of consent~3. Nulliparity~4. Singleton pregnancy~5. Cephalic Presentation~6. No contraindications to trial of labour or vaginal birth~7. Term pregnancy (37+0 to 42+0 weeks gestation)~8. Spontaneous onset of labour~9. In the ACTIVE phase of the FIRST stage of labour. Active labour is defined as:~   1. The presence of regular uterine contractions~  2. Cervical dilatation of ≥ 3 cm~  3. Cervical effacement of at least 80% (cervical length \< 1cm)~10. DYSTOCIA in the ACTIVE phase of FIRST stage of labour established by the Physician.~    1. Cervical change of \< 0.5 cm/hour over four hours OR~   2. NO cervical change in 2 hours~11. Ruptured amniotic membranes of at least 30 minutes~12. Normal fetal heart rate pattern at the time of randomization~Exclusion Criteria:~1. Serious medical condition (severe cardiac, pulmonary, or renal disease)~2. Known fetal anomaly~3. Known sensitivity to oxytocin~4. Contraindications to labour or vaginal birth (uterine scar)~5. Induced labour (using any method)~6. Oxytocin use prior to randomization~7. Second stage of labour~8. Suspected IUGR (\<5th percentile)~9. Suspected macrosomia at term (\>4500 grams)~10. Oligohydramnios (no 2x2 pocket of fluid on ultrasound prior to rupture of amniotic membranes)~11. Abnormal FHR pattern at the time of randomization~12. Suspected chorioamnionitis~13. Severe pre-eclampsia~14. Suspected placental abruption

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Accelerated Oxytocin Titration (Type: EXPERIMENTAL): None
- Gradual Oxytocin Titration (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility